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increased that the treatment groups will be im-
balanced with respect to important patient char-
acteristics in at least one subgroup. Stratification 
of the randomization is one approach for ensur-
ing balance with respect to certain factors, but the 
number of factors that can be controlled in this 
way is limited. Adjustment for patient character-
istics in the analysis of the data is another, and 
such adjustment can therefore be useful in sub-
group analyses. Finally, even when the treatment 
groups are balanced with respect to all important 
characteristics in every subgroup, false positive in-
teractions between treatment group and a patient 
characteristic will still lead to biased (e.g., exag-
gerated) estimates of treatment differences with-
in the corresponding subgroups, reinforcing the 
importance of properly controlling for type I errors 
in multiple-subgroup analyses.
Stephen W. Lagakos, Ph.D.
Harvard School of Public Health
Boston, MA 02115
Optic Neuritis
To the Editor: In her article on optic neuritis, 
Balcer (March 23 issue)1 points out that the pa-
tient with optic neuritis and multiple white-mat-
ter lesions, as seen on magnetic resonance imag-
ing of the brain, is at increased risk for multiple 
sclerosis (which is correct) and that the treatment 
of such patients with interferon beta reduces or 
delays the “development of multiple sclerosis” 
(which is not correct). No treatment has been 
shown to reduce or prevent the development of 
multiple sclerosis, except with reference to a re-
stricted window of time, which is clinically not a 
very meaningful way to think of therapy for a 
chronic, relapsing disease. As for delay, surely the 
optic neuritis must be regarded as the onset of the 
disease in these patients, so there can be no delay. 
By reducing the frequency of relapses,2-4 interferon 
beta delays the diagnosis of multiple sclerosis — a 
far less important outcome.
Les Dorfman, M.D.
Stanford University School of Medicine
Stanford, CA 94305
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Dr. Balcer replies: I agree with Dr. Dorfman 
that although interferon therapies may not ulti-
mately prevent multiple sclerosis in the setting of 
acute optic neuritis, a delay in the development of 
clinical demyelinating events and the diagnosis 
of multiple sclerosis is not likely to be an unim-
portant end point for a given patient.
Laura J. Balcer, M.D., M.S.C.E.
University of Pennsylvania School of Medicine
Philadelphia, PA 19104
lbalcer@mail.med.upenn.edu
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More on Donor-Derived T-Cell Leukemia 
after Bone Marrow Transplantation
To the Editor: In the case reported by Tamaki 
and Matsuoka (April 20 issue),1 there is no defi-
nite evidence of human T-cell lymphotropic virus 
type I (HTLV-I) infection in the hematopoietic 
stem-cell donor, and there seems to be no clonal-
ity marker such as monoclonal proviral integration 
in the donor. We therefore cannot conclude that 
adult T-cell leukemia–lymphoma (ATL) in the re-
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cipient was instigated by undetected HTLV-I in 
the asymptomatic donor. The possibility of an 
acquired infection of donor T cells by HTLV-I in 
the recipient has not been excluded. We propose 
that the profound immunosuppression attribut-
able to pretransplantation conditioning and pro-
phylaxis against post-transplantation graft-ver-
sus-host disease could have accelerated the 
development of ATL.2 Even if the donor was a 
healthy carrier of HTLV-I, proviral integration oc-
curs in only about 0.1 to 1.0 percent of periph-
eral-blood mononuclear cells. However, although 
it is “T-cell lymphotropic,” HTLV-I can infect extra-
hematopoietic cell types in vitro.3-5 Viral-genome 
sequencing could have shown the source of the 
HTLV-I.
Daniele Focosi, M.D.
Mario Petrini, M.D.
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The authors reply: We believe that the broth-
ers described in our report were infected with the 
same strain of HTLV-I because mother-to-child 
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transmission through breast-feeding is a primary 
route of infection.1 Furthermore, HTLV-I has lit-
tle variation in sequence.2 Indeed, we detected no 
difference in 5′−long-terminal-repeat and env se-
quences of HTLV-I provirus between the periph-
eral-blood leukocytes from the brothers and do-
nor-derived ATL cells. Sequencing the HTLV-I 
genome is a useless way to determine the origin 
of the donor ATL clone.
This clone was undetectable in the donor with 
the use of tumor-specific polymerase chain reac-
tion (PCR), but it was detectable in the recipient 
three weeks after transplantation. This period 
was too short for HTLV-I–infected cells to expand 
clonally after HTLV-I infection in the recipient. 
In addition, the DNA methylation pattern of 
HTLV-I provirus in donor-derived ATL cells was 
similar to that in asymptomatic carriers. These 
findings suggest that the clone existed in the 
donor as a minor population below the sensitiv-
ity of PCR, although we cannot completely exclude 
the possibility of a new infection in the recipient 
after transplantation.
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EGFR Mutations in Small-Cell Lung Cancers 
in Patients Who Have Never Smoked
To the Editor: Mutations in the epidermal 
growth factor receptor gene (EGFR) occur in 10 to 
20 percent of non–small-cell lung cancers, spe-
cifically adenocarcinomas, and are associated with 
the response to EGFR tyrosine kinase inhibitors 
(erlotinib and gefitinib).1 However, the results of 
screening of small-cell lung cancers for EGFR mu-
tations have been negative.2 Thus, small-cell lung 
cancers are not routinely tested for EGFR muta-
tions, nor have they been systematically evaluated 
for responsiveness to EGFR tyrosine kinase in-
hibitors.
A 45-year-old woman who had never smoked 
and who had masses in the right lung, pleura, 
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